If a blood pressure change appears after starting sermorelin, tell the clinician rather than assuming it is an expected adjustment. A reading cannot identify the cause by itself. The available hormone-pathway information also does not establish a reliable percentage risk for every compounded sermorelin prescription.

Call 911 for symptoms such as chest pain, severe shortness of breath, or sudden weakness or trouble speaking. A reading above 180 systolic or 120 diastolic with concerning symptoms is a medical emergency; do not wait for a peptide provider’s portal reply or for the number to fall on its own.

The considered take

Respond to the reading and symptoms first. Investigating whether sermorelin contributed is a separate clinical question.

A hormone pathway is not a personal forecast

NIDDK describes high blood pressure among possible complications of acromegaly, a condition involving excessive growth hormone. That explains why growth hormone and cardiovascular health can belong in the same discussion. It does not mean that taking a prescribed sermorelin preparation is equivalent to having acromegaly.

Likewise, another peptide's side-effect list cannot supply your risk estimate. Ask the clinician what evidence applies to the proposed product and what your existing history changes about the decision. Our diabetes guide makes the same distinction for glucose-related concerns.

Sources: NIDDK: Acromegaly · Sigalos and Pastuszak: Safety and efficacy of growth hormone secretagogues

Use a measurement the clinician can interpret

If you monitor at home, use a validated upper-arm monitor with the correct cuff size and follow its instructions. The American Heart Association recommends quiet rest before a reading, supported positioning, and keeping a record rather than interpreting one isolated measurement as the whole pattern.

Write down the time, both numbers, relevant symptoms, and recent medicine changes. Do not repeatedly measure until you obtain a number you prefer. Bring the monitor to an appointment if its results seem inconsistent, and ask your clinician what monitoring schedule and target make sense for you.

Sources: American Heart Association: Home blood pressure monitoring

Know when a high reading needs immediate attention

For an unexpectedly very high reading without emergency symptoms, AHA advises waiting at least one minute and measuring again. If the top number remains above 180 or the bottom number above 120, contact a health professional immediately. With the concerning symptoms described above, call 911 rather than delaying for repeated measurements.

These are general urgent-response thresholds, not a target range for your treatment. Do not take an extra blood pressure tablet, skip a medicine, or change sermorelin on the basis of this article. Follow a clinician-provided action plan if you have one.

Sources: American Heart Association: Home blood pressure monitoring

Review the full medication and symptom timeline

Tell the care team about prescriptions, over-the-counter products, supplements, and changes in pain, sleep, or illness. Include the date sermorelin began and any refill or formulation change. The interaction guide helps organize that information.

Ask who will review the readings and whether the proposed treatment still makes sense. If you also notice swelling or rapid weight change, report it rather than treating it as proof of muscle growth. Read water retention and weight gain for the separate questions that raises.

If a headache is part of the change, see the headache guide for warning signs that should not wait for routine follow-up.

Sources: FDA: Drug interactions, what you should know · FDA: Managing the benefits and risks of medicines · DailyMed: EGRIFTA WR prescribing information

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. NIDDK: AcromegalyNIH patient education · Explains effects of pathological GH excess; does not estimate diabetes risk from prescribed sermorelin.
  2. Sigalos and Pastuszak: Safety and efficacy of growth hormone secretagoguesClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
  3. American Heart Association: Home blood pressure monitoringProfessional medical organization · General measurement and urgent-response guidance; not a sermorelin trial or an individual blood pressure target.
  4. FDA: Drug interactions, what you should knowUS regulator · General medicine, food and supplement interaction principles, not an exhaustive sermorelin interaction list.
  5. FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
  6. DailyMed: EGRIFTA WR prescribing informationClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.